Literature DB >> 3484629

The binding of the calcium channel blocker, bepridil, to calmodulin.

H Itoh, T Tanaka, Y Mitani, H Hidaka.   

Abstract

Bepridil had the highest relative potency for inhibition of myosin light chain kinase (MLCK) activated by Ca2+-calmodulin of all the calcium channel blockers we examined. Kinetic analysis indicated that the primary effect of bepridil was mediated through a competitive inhibition of the enzyme activation by interaction with calmodulin and the apparent Ki value of this agent was 2.2 microM. We then examined the binding of bepridil to calmodulin, using the equilibrium column binding technique. [3H]bepridil bound to the calcium-calmodulin complex, but not to calmodulin in the presence of 2 mM EGTA. Scatchard analysis of the binding of bepridil to calmodulin demonstrated that the dissociation constant was 6.2 microM and the calculated number of specific binding sites was about 5 sites per molecule of calmodulin. The concentrations of unlabeled bepridil, W-7, prenylamine, verapamil and diltiazem producing 50% inhibition (IC50) of the binding of [3H]bepridil to calmodulin were 4 microM, 28 microM, 45 microM, 130 microM and 700 microM, respectively. However, nifedipine and nicardipine did not displace [3H]labeled bepridil from calmodulin. There was a good correlation between the displacement of [3H]bepridil from calmodulin and the inhibitory effect on MLCK by these calcium channel blockers and W-7. These results suggest that bepridil binds to calmodulin in the presence of calcium and potently inhibits the phosphorylation of myosin light chain.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484629     DOI: 10.1016/0006-2952(86)90516-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Targeting the sarcomere to correct muscle function.

Authors:  Peter M Hwang; Brian D Sykes
Journal:  Nat Rev Drug Discov       Date:  2015-04-17       Impact factor: 84.694

2.  The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin.

Authors:  J M Lamers; P D Verdouw; J Mas-Oliva
Journal:  Mol Cell Biochem       Date:  1987-12       Impact factor: 3.396

3.  Comparative effects of bepridil, its quaternary derivative CERM 11888 and verapamil on caffeine-induced contracture in ferret hearts.

Authors:  J Leboeuf; C Leoty; J C Lamar; R Massingham
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

4.  Blockade by calmodulin inhibitors of Ca2+ channels in smooth muscle from rat vas deferens.

Authors:  K Nakazawa; K Higo; K Abe; Y Tanaka; H Saito; N Matsuki
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

Review 5.  Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.

Authors:  L M Hollingshead; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

6.  Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca2+ signalling.

Authors:  Serena Stadler; Chi Huu Nguyen; Helga Schachner; Daniela Milovanovic; Silvio Holzner; Stefan Brenner; Julia Eichsteininger; Mira Stadler; Daniel Senfter; Liselotte Krenn; Wolfgang M Schmidt; Nicole Huttary; Sigurd Krieger; Oskar Koperek; Zsuzsanna Bago-Horvath; Konstantin Alexander Brendel; Brigitte Marian; Oliver de Wever; Robert M Mader; Benedikt Giessrigl; Walter Jäger; Helmut Dolznig; Georg Krupitza
Journal:  Cell Mol Life Sci       Date:  2016-12-24       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.